IRIS - Res&Arch Institutional Research Information System - Research & Archive

MANDALA', Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.692
AS - Asia 3.668
EU - Europa 2.476
SA - Sud America 666
AF - Africa 52
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 10
Totale 11.585
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.610
SG - Singapore 2.037
RU - Federazione Russa 753
IE - Irlanda 717
BR - Brasile 574
HK - Hong Kong 517
IT - Italia 512
CN - Cina 456
VN - Vietnam 370
DE - Germania 134
KR - Corea 105
GB - Regno Unito 76
AT - Austria 58
FI - Finlandia 43
UA - Ucraina 40
AR - Argentina 35
CA - Canada 33
MX - Messico 31
BD - Bangladesh 29
SE - Svezia 29
TR - Turchia 27
EU - Europa 20
PL - Polonia 20
IN - India 18
ES - Italia 17
FR - Francia 17
ZA - Sudafrica 17
IQ - Iraq 16
NL - Olanda 16
JP - Giappone 15
PK - Pakistan 12
CH - Svizzera 11
EC - Ecuador 11
GR - Grecia 11
ID - Indonesia 9
UZ - Uzbekistan 9
VE - Venezuela 9
CL - Cile 8
CO - Colombia 8
AU - Australia 7
PE - Perù 7
PY - Paraguay 7
DZ - Algeria 6
EG - Egitto 6
LT - Lituania 6
MA - Marocco 6
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
IL - Israele 4
PS - Palestinian Territory 4
AZ - Azerbaigian 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
JO - Giordania 3
NP - Nepal 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
UY - Uruguay 3
BB - Barbados 2
BE - Belgio 2
HN - Honduras 2
IR - Iran 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
LY - Libia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PT - Portogallo 2
TN - Tunisia 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BW - Botswana 1
BZ - Belize 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
KY - Cayman, isole 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NE - Niger 1
NI - Nicaragua 1
PA - Panama 1
PH - Filippine 1
PW - Palau 1
RS - Serbia 1
Totale 11.578
Salva come PNG Salva come JPEG
Città #
Singapore 1.343
Chandler 944
Dublin 716
Hong Kong 510
Boardman 285
Dong Ket 273
Altamura 269
Santa Clara 268
San Mateo 233
Medford 215
Princeton 212
Lawrence 207
Andover 186
Moscow 182
Los Angeles 146
Wilmington 121
Ashburn 120
Seoul 105
Arezzo 57
Redwood City 56
São Paulo 53
New York 50
Des Moines 45
Nuremberg 44
Piscataway 43
Norwalk 42
Perugia 39
San Paolo di Civitate 39
Ho Chi Minh City 27
Shanghai 27
Helsinki 24
Munich 23
Redmond 23
Hanoi 22
Vienna 22
Hefei 21
Chicago 20
The Dalles 20
San Francisco 19
Dallas 18
Montreal 17
Rio de Janeiro 17
Tianjin 17
Belo Horizonte 16
Brooklyn 16
Kocaeli 16
Milan 16
Warsaw 16
Brasília 15
London 15
Guangzhou 14
Saint Petersburg 14
Tokyo 14
Beijing 13
Columbus 12
Jacksonville 11
Atlanta 10
Boston 10
Johannesburg 10
Mexico City 10
Curitiba 9
Falkenstein 9
Porto Alegre 9
Shijiazhuang 9
Turku 9
Haiphong 8
Secaucus 8
Leighton Buzzard 7
Ribeirão Preto 7
Stockholm 7
Asunción 6
Baghdad 6
Caxias do Sul 6
Changsha 6
Frankfurt am Main 6
Guayaquil 6
Manaus 6
Manchester 6
Phoenix 6
Recife 6
Salvador 6
St Petersburg 6
Toronto 6
Charlotte 5
Chennai 5
Da Nang 5
Denver 5
Dhaka 5
Florence 5
Florianópolis 5
Houston 5
Palmas 5
Philadelphia 5
Poplar 5
Rome 5
Seville 5
Volta Redonda 5
Woodbridge 5
Xi'an 5
Zhengzhou 5
Totale 7.593
Salva come PNG Salva come JPEG
Nome #
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action 113
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 89
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 triaL 86
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial 85
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma 81
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 80
Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703 79
A prospective study on survival in cancer patients with and without venous thromboembolism. 78
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism 78
Chemotherapy-associatedthromboembolic risk in cancer outpatients and effect of nadroparinthromboprophylaxis: results of a retrospective analysis of the PROTECHT study. 76
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma 75
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 74
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma 73
Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma 71
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin 70
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 69
40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH 68
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday 68
Acute endocrine effects of interleukin-12 in cancer patients 67
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients 67
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling 67
Adjuvant therapy in breast cancer and venous thromboembolism 66
Acute dyspnea due to right phrenic palsy during infusional chemotherapy 66
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i 65
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management 65
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 65
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 64
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 64
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial 61
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 61
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 61
Tissue prognostic biomarkers in primary cutaneous melanoma 60
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 60
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee 59
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study 59
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases 59
Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action 58
AKT-ions with a TWIST between EMT and MET 58
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial 58
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma 57
Adjuvant therapy of colon cancer. State of the art and future perspectives 57
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 57
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 57
Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases 57
Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma 56
Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 56
Treatment of venous thromboembolism in cancer patients: The dark side of the moon 56
Is there a right-sided shift for colorectal cancer in women compared with men? 55
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis 55
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease 55
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma 55
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 54
Insights Into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1 54
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications 54
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives 54
Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study 54
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic 53
Melanoma brain metastases: review of histopathological features and immune-molecular aspects 53
The density and spatial tissue distribution of CD8+ and CD163+immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors 53
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma 52
Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy 52
Venous thromboembolism and cancer: new issues for an old topic 52
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study 52
Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia 52
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib 52
Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights 52
Targeted therapy for advanced cutaneous melanoma 51
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. 51
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 51
Self-monitoring versus standard monitoring of oral anticoagulation 51
Targeting BRAF in melanoma: Biological and clinical challenges 51
Squamoproliferative skin lesion during braf inhibitors:one size does not fit all 51
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer 51
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortiuM 51
SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study 51
An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system 50
GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis 50
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) 50
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p 50
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome 50
Bisphosphonates and metastatic bone disease 50
Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma 50
Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome 50
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility 50
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 50
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 49
Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon 49
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial 49
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma 49
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition 49
What is the real benefit of adjuvant chemotherapy in the Adjuvant Navelbine International Trialist Association trial? 49
A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy 49
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma 48
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience' 48
The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma 48
Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer 48
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 47
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial 47
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: A multicenter international retrospective study 47
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program 47
Totale 5.871
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.024
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.024
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021653 0 0 0 0 0 1 268 6 19 51 16 292
2021/20221.188 8 227 9 2 18 7 31 444 9 44 165 224
2022/20233.040 217 524 28 237 274 391 0 164 1.062 9 95 39
2023/2024981 90 154 53 28 18 5 143 9 96 122 99 164
2024/20253.186 34 296 24 82 406 143 92 136 1.173 258 285 257
2025/20262.876 644 444 267 492 841 188 0 0 0 0 0 0
Totale 11.962